AIM ImmunoTech Announces New Pre-Clinical Data Showing Ampligen As Part Of Combination Therapy Slows Melanoma Tumor Growth And Improves Survival In Mouse Model
Portfolio Pulse from Benzinga Newsdesk
AIM ImmunoTech has announced new pre-clinical data indicating that its drug Ampligen, when used as part of a combination therapy, slows melanoma tumor growth and improves survival in a mouse model.
July 24, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AIM ImmunoTech's pre-clinical data shows that its drug Ampligen, as part of a combination therapy, can slow melanoma tumor growth and improve survival in a mouse model. This positive development could boost investor confidence and potentially drive the stock price up in the short term.
The announcement of positive pre-clinical data for Ampligen in combination therapy for melanoma is likely to boost investor confidence. This could lead to a short-term increase in AIM's stock price as the market reacts to the potential of this therapy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100